If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
400.00    0.00 (0.00%)
Bid:
395.00
Ask:
405.00
Spread: 10.00 (2.532%)
Market Cap: £191.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Director/PDMR Shareholding

26 Mar 2025 10:30

RNS Number : 3167C
Tristel PLC
26 March 2025
 

Tristel plc

("Tristel" or the "Company")

 

Director/PDMR Shareholding

CEO buys shares

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that Matthew Sassone, Chief Executive Officer of the Company, has purchased 3,500 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 310 pence per Ordinary Share.

 

As a result, Matthew Sassone's beneficial interest in the Company is 3,500 Ordinary Shares, representing 0.007 per cent. of the total issued share capital.

 

 

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Matt Sassone, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391303

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash / Camilla Hume / Trisyia Jamaludin (Corporate Finance)

Sunila de Silva (ECM)

Louise Talbot (Sales)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

  

 

 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 which forms part of UK Law by virtue of the European Union (Withdrawal) Act 2018.

 

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Matthew Sassone

2. 

Reason for the Notification

a)

Position/status

CEO

b)

Initial notification/Amendment

Initial notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 1p each

Identification code

GB00B07RVT99 

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

310 pence, 3,500 shares

 

 

d)

Aggregated information:

· Aggregated volume

· Price

See above

 

e)

Date of the transaction

26 March 2025

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGZFGVFGKZM
Date   Source Headline
23rd Apr 20187:00 amRNSEPA approval received
13th Apr 20182:55 pmRNSIssue of Equity
27th Mar 20188:19 amRNSIssue of Equity
26th Mar 20187:00 amRNSCommercial collaboration with Parker Laboratories
8th Mar 201810:58 amRNSIssue of Equity
20th Feb 20187:00 amRNSHalf-year Report
8th Feb 20182:19 pmRNSHolding(s) in Company
26th Jan 20187:00 amRNSIssue of Equity
24th Jan 20187:00 amRNSStudy shows comparable efficacy of Tristel Wipes
17th Jan 20187:00 amRNSInvestor results presentation
12th Dec 20172:57 pmRNSResult of AGM
12th Dec 20177:00 amRNSAGM Statement & notice of results
27th Nov 201710:35 amRNSIssue of Equity
23rd Nov 20173:24 pmRNSClarification of AGM timing
14th Nov 201710:34 amRNSIssue of Equity
2nd Nov 20177:00 amRNSDirectors dealing/grant of options
23rd Oct 20174:41 pmRNSIssue of Equity
19th Oct 20177:01 amRNSDirector Appointment
19th Oct 20177:00 amRNSFinal Results
3rd Oct 20177:00 amRNSTiming of EPA approval
19th Sep 20177:00 amRNSInvestor results presentation
18th Sep 20171:44 pmRNSIssue of Equity
22nd Aug 201712:08 pmRNSIssue of Equity
18th Aug 20171:31 pmRNSDirector/PDMR Dealing - replacement
17th Aug 20177:00 amRNSDirector/PDMR Dealing
7th Aug 20172:29 pmRNSIssue of Equity
24th Jul 20179:46 amRNSIssue of Equity
19th Jul 20177:00 amRNSTrading update & Notice of results
5th Jul 20177:00 amRNSIssue of Equity
3rd Jul 20171:59 pmRNSStrategic investment
3rd Jul 20177:00 amRNSSubmission to EPA & subsidiary incorporated in USA
13th Jun 20177:00 amRNSIssue of Equity
24th May 20177:00 amRNSShareholder Open Day & Notice of Trading Update
19th May 20173:34 pmRNSIssue of Equity
3rd May 20178:27 amRNSIssue of Equity
7th Apr 20175:04 pmRNSResult of Placing
7th Apr 20172:07 pmRNSProposed Secondary Placing
28th Mar 20172:38 pmRNSIssue of Equity
7th Mar 20179:41 amRNSIssue of Equity
6th Mar 20177:00 amRNSIssue of Equity
27th Feb 20177:00 amRNSProducts approved by Australia's TGA
27th Feb 20177:00 amRNSJournal of Ultrasound in Medicine & Biology
23rd Feb 20177:00 amRNSHalf-year Report
25th Jan 20177:00 amRNSInvestor results presentation
24th Jan 20177:00 amRNSJournal of Infection Prevention: TSTL wipes study
17th Jan 201712:31 pmRNSDirector / PDMR Shareholding
13th Dec 201612:30 pmRNSResult of AGM
13th Dec 20167:00 amRNSAGM Statement
6th Dec 20167:00 amRNSIssue of Equity
28th Nov 20163:42 pmRNSNotice of AGM correction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.